EUVIMEDEUVIMED entdecken
Crossref

Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control

Moses Philip, Abdul Khader Karakka Kal iD, Michael Benedict Subhahar iD, Tajudheen K Karatt iD, Fatma Mohammed Graiban, Meleparappil Muhammed Ajeebsanu, Marina Joseph, Shantymol V Jose

Drug Testing and Analysis · 2025

DOI: 10.1002/dta.3822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Moses Philip und 7 weiteren Autor:innen. Beteiligte Einrichtung: Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, UAE. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Aminopyridines, Benzamides, Doping in Sports. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phosphodiesterase 4 (PDE4) inhibitors constitute a relatively modern class of medications that are known for inducing bronchodilation and exhibiting anti‐inflammatory properties within the body. Due to these properties, there is concern regarding their potential misuse as performance‐enhancing substances in competitive sports. This study delves into the metabolic conversion of roflumilast in thoroughbred horses following oral administration and in vitro experimentation using equine liver microsomes and Cunninghamella elegans . High‐performance liquid chromatography coupled with a Q Exactive Orbitrap mass spectrometer (HPLC‐HRMS) was employed for analysis. The investigation identified 10 metabolites of roflumilast, including six phase I and four phase II metabolites from in vivo studies, and 11 metabolites from in vitro studies, consisting of eight phase I and three phase II metabolites. The identified biotransformation products encompassed processes such as hydroxylation, chlorine substitution, methylation, N ‐oxide formation, and even the dissociation of methylenecyclopropane and difluoromethane. Furthermore, the study identified three glucuronic acid and one sulfonic acid conjugated phase II metabolites of the investigated drug candidate. The aforementioned findings contribute to the detection and comprehension of the unauthorized utilization of roflumilast in equestrian sports.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsAminopyridinesBenzamidesDoping in SportsAnimalsHorsesCyclopropanesMicrosomes, LiverChromatography, High Pressure LiquidSubstance Abuse DetectionAdministration, OralTandem Mass Spectrometry

Stichwörter der Autor:innen

Cunninghamella elegansPDE4Roflumilastdoping controlequine liver microsomesin vivophosphodiesterase 4 inhibitors

Substanzen

RoflumilastPhosphodiesterase 4 InhibitorsAminopyridinesBenzamidesCyclopropanes

Autor:innen und Institutionen

  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, UAE.
  • Department of Bacteriology, Diagnostic Section, Central Veterinary Research Laboratory, Dubai, UAE.

ORCID-Profile: Abdul Khader Karakka Kal, Michael Benedict Subhahar, Tajudheen K Karatt

Zitieren

APA

Philip, M., Karakka Kal, A. K., Subhahar, M. B., Karatt, T. K., Graiban, F. M., Ajeebsanu, M. M., Joseph, M., & Jose, S. V. (2025). Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control. Drug Testing and Analysis. https://doi.org/10.1002/dta.3822

Vancouver

Philip M, Karakka Kal AK, Subhahar MB, Karatt TK, Graiban FM, Ajeebsanu MM, et al. Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control. Drug Testing and Analysis. 2025. doi:10.1002/dta.3822

BibTeX
@article{Philip2025,
  author = {Philip, Moses and Karakka Kal, Abdul Khader and Subhahar, Michael Benedict and Karatt, Tajudheen K and Graiban, Fatma Mohammed and Ajeebsanu, Meleparappil Muhammed and Joseph, Marina and Jose, Shantymol V},
  title = {Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control},
  journal = {Drug Testing and Analysis},
  year = {2025},
  doi = {10.1002/dta.3822}
}
Kostenlos starten →